CYP2E1 and Parkinson disease: Furthermore, melatonin or silymarin treatment has been associated with the inhibition of paraquat- and maneb-induced dopaminergic degeneration and oxidative damage in PD mouse models, accompanied by decreased CYP2E1 expression [149].